Second Quarter of the Fiscal Year Ending March 31, 2026
Sales composition ratio
Pharmaceutical Wholesale Business
In the pharmaceutical wholesale business, although there were negative impacts from factors such as the drug price revision and a decrease in sales at some facilities in localized areas due to competitive bidding, sales increased slightly as efforts to focus on the sale of products eligible for the price maintenance premium, mainly anticancer drugs, outweighed the decrease in revenue. On the profit side, however, profit decreased due to the impact of the aforementioned sales decline from competitive bidding and an increase in selling, general and administrative expenses. As a result of the above, net sales were 281,967 million yen (100.9% of the same period of the previous year), and segment profit (operating profit) was 2,080 million yen (76.4% of the same period of the previous year).
Pharmacy Business
In the pharmacy business, although the number of prescriptions received decreased, revenue increased due to efforts to increase income from dispensing technical fees and pharmaceutical management fees. On the profit side, profit increased due to efforts to calculate dispensing fees related to family pharmacy functions and to manage costs. As a result of the above, net sales were 9,870 million yen (101.5% of the same period of the previous year), and segment profit (operating profit) was 135 million yen (141.3% of the same period of the previous year).
Veterinary Drug Wholesale Business
In the Veterinary Drug Wholesale Business, revenue increased, partly due to the consolidation of Arrow Medical Inc., which offset the negative impact of a changeover in products as some products began to be sold directly by the manufacturer. On the profit side, however, profit decreased as the effect of the increase in revenue was not enough to absorb the increase in costs resulting from the consolidation. As a result, net sales were ¥6,178 million (109.4% of that of the same period of the previous year), and segment profit (operating profit) was ¥108 million (75.1% of that of the same period of the previous year).
Pharmaceutical Business (business of supporting introduction of unapproved drugs)
The Pharmaceutical Business (business of supporting introduction of unapproved drugs) is a new business launched in the current fiscal year, and no sales were posted in the consolidated six-month period, while research and development expenses came to ¥592 million, and segment loss (operating loss) amounted to the same amount of ¥592 million.
Nursing Care-related Rental and Other Business
In the Nursing Care-related Rental and Other Business, revenue increased due to factors including the consolidation of Kyowa Transportation Co., Ltd. in April 2025.On the profit side, the segment loss increased, as increases in selling, general and administrative expenses due to price rises, including personnel and fuel costs, could not be absorbed. As a result, net sales were ¥2,217 million (102.4% of that of the same period of the previous year), and segment loss (operating loss) was ¥122 million (segment loss for the same period of the previous year was ¥88 million).